The main goal of this study is to provide treatment with cannabidiol (CBD) to children with
drug resistant epilepsy through a Physician Expanded Access Investigation New Drug protocol.
As the controlled therapeutic use of CBD in children is novel, the primary objective of this
study is to evaluate the safety and efficacy of CBD when administered as adjunctive therapy
in children that have exhausted the majority of FDA approved antiepileptic drug treatment
options.